Compare Primo Brands Corporation Class A Common Stock (PRMB) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Primo Brands Corporation Class A Common Stock vs Stryker Corporation — how do they compare? Primo Brands Corporation Class A Common Stock trades at $18.64 (market cap $6.84B), while Stryker Corporation trades at $282 (market cap $108.38B). The key difference: Stryker Corporation is far larger — about 15.8× Primo Brands Corporation Class A Common Stock's market cap, and Primo Brands Corporation Class A Common Stock pays the higher dividend (2.54%). Which is the better fit depends on your goals — on Pluang, investors hold Primo Brands Corporation Class A Common Stock for 0 Days and Stryker Corporation for 22 Days on average.
| PRMB | SYK | |
|---|---|---|
Market Cap | $6.84B | $108.38B |
Volume | 2,864,594 | 2,068,363 |
Sector | Consumer Staples | Health |
52-Week High | $25.39 | $388.35 |
52-Week Low | $14.46 | $269.75 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $12.17B | $119.84B |
Dividend Yield | 2.54% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PRMB trades at $18.9, down 1.46% on the day, with a neutral technical signal and key support/resistance clustered around $19. The company reported Q2 2026 EPS of $0.37, beating expectations, and shows improving revenue and net income trends for 2026. Recent news highlights expansion with a new factory opening and strong premium water sales growth, supporting a positive analyst consensus.
The outlook is positive, driven by sales momentum and capacity expansion, but risks include thin net margins and high P/E ratio. With 80% of analysts rating it Buy and a consensus price target of $28.50, the stock offers significant upside potential if execution continues, though margin pressure remains a key watchpoint.
Stryker (SYK) trades at $282.63, showing minimal daily movement. The stock exhibits a neutral technical stance with mixed moving averages and oscillators. Fundamentally, SYK maintains strong profitability with a 14.43% net income margin and 16.51% ROE, though a P/E of 29.28 suggests a premium valuation. Recent news highlights ongoing legal scrutiny over a manufacturing issue disclosed in September 2026, which caused a significant price drop. Q3 2026 earnings are anticipated on October 29, 2026, following a mix of beats and misses in prior quarters.
The outlook for SYK is cautiously optimistic, supported by analyst consensus with a $365.89 price target and no sell ratings. Investment appeal lies in its solid cash flow and market position, but risks include legal investigations and persistent operational challenges. The stock's near-term direction will likely hinge on Q3 earnings results and clarity on the manufacturing issue resolution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Primo Brands Corporation Class A Common Stock
Primo Brands Corporation is a branded beverage company that produces and distributes packaged and purified water, water dispensers, and filtration equipment across North America, under brands including Poland Spring, Pure Life, Arrowhead, and Primo Water.
Read more on PRMB →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
